ABL Diagnostics: its Texcell division partners with Abionyx Pharma on CER-001
ABL Diagnostics announced on September 10, 2026 the conclusion of a partnership between its Texcell division and Abionyx Pharma. Texcell will conduct safety and viral clearance studies related to the candidate drug CER-001.
Texcell selected for viral safety studies of CER-001
ABL Diagnostics (Euronext Paris: ABLD), specializing in molecular diagnostic solutions, health software and clinical research services, has concluded a strategic partnership with Abionyx Pharma (FR0012616852), a biopharmaceutical company developing therapies for sepsis and intensive care based on an apoA-I technology platform.
Under this agreement, the Texcell division will conduct safety and viral clearance studies associated with the preparation of validation batches for the CER-001 manufacturing process, a candidate biological drug developed by Abionyx Pharma in several indications, including LCAT deficiency.
A milestone in Abionyx Pharma's industrial and regulatory program
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Viral safety studies aim to demonstrate the capacity of manufacturing processes to eliminate or inactivate potential viral contaminants, in accordance with the expectations of international regulatory authorities.
According to ABL Diagnostics, the solutions developed by Texcell meet the scientific, quality and regulatory standards required for the major global markets, particularly in Europe, the United States and Asia.
A convergence with ABL Diagnostics' other areas of expertise
Since its integration within ABL Diagnostics, the Texcell division has benefited from an expanded scientific environment combining viral safety, molecular diagnostics, microbiology, virology, sequencing and genomic analysis.
Chalom Sayada, Chief Executive Officer of ABL Diagnostics, stated: "The choice of Texcell to support this strategic step in the development of CER-001 illustrates the international recognition of our expertise in viral safety and clearance."
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
1 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 13,8 millions d'euros
Management commentary: Sur la base des informations commerciales, opérationnelles et comptables disponibles à la date du présent communiqué, la Société anticipe désormais un chiffre d'affaires compris entre 13,5 M€ et 14,0 M€. Cette fourchette actualise l'objectif de 12,265 M€ publié le 1er juin 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
